http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150034209-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-336 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| filingDate | 2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150034209-A |
| titleOfInvention | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| abstract | Disclosed are methods and compositions suitable for the treatment of malignant tumors of a subject having a mutant or dysregulated AHI1 gene or triggering apoptosis of tumor cells in a subject having a germline cell deletion polymorphism that blocks the activity of a thymidine kinase inhibitor. These methods include alkylated hexitol derivatives such as dianhydrogalactitol, derivatives or analogs of dianhydrogalactitol, derivatives or analogs of diacetyl dianhydrogalactitol, diacetyl dianhydrogalactitol, dibromoducitol, and dibromodule Cytol derivatives or analogs are used. The composition may include such alkylated hexitol derivatives. The method may further comprise administration of a BH3 mimetic, and the composition may further comprise a BH3 mimetic. In a subject suffering from difficulty in regulating the AHI1 gene, the method may further comprise administering a substance that modulates the expression or activity of the AHI1 gene or AHI1 protein, and the composition may further comprise such a substance. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190086569-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019172681-A1 |
| priorityDate | 2012-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3625.